Additionally, in order to pare costs and share information effectively, Flaig is looking to dramatically cut back on thenumber of suppliers Iomega uses.
They will be lookingback at the molecular characterisation of the tumours in a number of common cancers stored at the Wales Cancer Bank to discover "molecular fingerprints", known as biomarkers.